These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results
- Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday.
- 05/13/2025
|
Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brendan Strong - Senior Vice President, Investor Relations & Corporate Communications Richard Paulson - President & Chief Executive Officer Reshma Rangwala - Chief Medical Officer & Head, Research Sohanya Cheng - Chief Commercial Officer & Head, Business Development Lori Macomber - Chief Financial Officer & Treasurer Conference Call Participants Colleen Kusy - Baird Ted Tenthoff - Piper Sandler Peter Lawson - Barclays Albert Agustinus - Leerink Partners Operator Good afternoon. My name is Chloe, and I will be your conference operator today.
- 05/13/2025
|
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates
- Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.77 per share versus the Zacks Consensus Estimate of a loss of $4.21. This compares to loss of $4.80 per share a year ago.
- 05/12/2025
|
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification
- – New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns of Expired 80 mg and 100 mg Units – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Company is Exploring Various Alternatives to Extend Cash Runway – – Conference Call Scheduled for Today at 4:30 p.m. ET – NEWTON, Mass.
- 05/12/2025
|
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
- -- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass.
- 05/08/2025
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , May 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 983 restricted stock units (RSUs) to two newly-hired employees.
- 05/01/2025
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , April 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees.
- 04/01/2025
|
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
- - XPOVIO ® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO ® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC.
- 03/05/2025
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , March 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 3,316 restricted stock units (RSUs) to five newly-hired employees.
- 03/03/2025
|
Karyopharm Announces 1-for-15 Reverse Stock Split
- NEWTON, Mass. , Feb. 24, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m.
- 02/24/2025
|
Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q4 2024 Earnings Call February 19, 2025 8:00 AM ET Company Participants Brendan Strong - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - CMO & Head of Research Sohanya Cheng - CCO & Head of Business Development Lori Macomber - EVP, CFO, & Treasurer Conference Call Participants Colleen Kusy - Baird Maury Raycroft - Jefferies Unidentified Analyst - Barclays Jonathan Chang - Leerink Partners Unidentified Analyst - RBC Capital Markets Ed White - H.C. Wainwright Operator Good morning.
- 02/19/2025
|
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.36 per share a year ago.
- 02/19/2025
|
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
- – Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Million for Full Year 2024 – – Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 – – Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkpoint Inhibitors.
- 02/19/2025
|
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
- XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market in which XPOVIO® has been approved for public health insurance coverage.
- 02/13/2025
|
Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
- -- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET -- NEWTON, Mass.
- 02/12/2025
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , Feb. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 28,000 restricted stock units (RSUs) to three newly-hired employees.
- 02/03/2025
|
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
- – Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 – – Recently Announced Key Leadership Changes, including the Appointment of Lori Macomber as Chief Financial Officer and Brendan Strong as SVP of Investor Relations and Corporate Communications – – Preliminary Unaudited Full Year 2024 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $113 Million, Respectively – NEWTON, Mass. , Jan. 13, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2024 achievements and 2025 objectives.
- 01/13/2025
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 101,250 shares of Karyopharm's common stock and an aggregate of 108,540 restricted stock units (RSUs) to four newly-hired employees.
- 01/02/2025
|
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer
- NEWTON, Mass. , Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025.
- 01/02/2025
|
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
- NEWTON, Mass. , Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications.
- 12/09/2024
|
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
- NEWTON, Mass. , Dec. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding the evolving treatment landscape in endometrial cancer and any implications this may have with respect to the Company's Phase 3 XPORT-EC-042 trial.
- 12/03/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , Dec. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 4,800 restricted stock units (RSUs) to two newly-hired employees.
- 12/02/2024
|
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
- NEWTON, Mass. , Nov. 25, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36th Annual Healthcare Conference in a fireside chat on Tuesday, December 3 at 11:30 a.m.
- 11/25/2024
|
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
- NEWTON, Mass. , Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.
- 11/20/2024
|
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
- NEWTON, Mass. , Nov. 18, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego, CA.
- 11/18/2024
|
Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Elhan Webb - Senior Vice President, Investor Relations Richard Paulson - President and Chief Executive Officer Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Ed White - H.C. Wainwright Peter Lawson - Barclays Maury Raycroft - Jefferies Operator Good morning.
- 11/05/2024
|
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
- SHANGHAI and HONG KONG , Nov. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present the latest data from two clinical studies of selinexor in two Posters at the 2024 American Society of Hematology Annual Meeting (ASH 2024), taking place on December 7-10, 2024, in San Diego, CA, the United States. Details on the Posters: Title: Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase III Bench Study Publication Number: 4748 Session: 654.
- 11/05/2024
|
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.
- 11/05/2024
|
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
- – Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass. , Nov. 5, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.
- 11/05/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , Nov. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,500 restricted stock units (RSUs) to three newly-hired employees.
- 11/01/2024
|
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/31/2024
|
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
- -- Conference Call Scheduled for Tuesday, November 5, 2024, at 8:00 a.m. ET -- NEWTON, Mass.
- 10/31/2024
|
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
- Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) Remains a Co-primary Endpoint Promising Improvement in Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial Proactively Increasing Total Sample Size of the SENTRY Trial to Approximately 350 Patients to Further Increase the Statistical Powering; Expected Top-line Data Read-out Remains in 2H 2025 Company to Host a Conference Call Today at 8:00 a.m. ET Featuring Drs.
- 10/31/2024
|
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
- Company to host a conference call tomorrow at 8:00 a.m. ET NEWTON, Mass.
- 10/30/2024
|
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country
- This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the third approved indication of the drug in South Korea. To date, XPOVIO® has already been included in national health insurance or reimbursement schemes in South Korea, the mainland of China, Australia and Singapore, and is expected to achieve national reimbursement coverage in more APAC markets.
- 10/17/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , Oct. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 17,000 restricted stock units (RSUs) to three newly-hired employees.
- 10/01/2024
|
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
- XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. XPOVIO® has been approved for multiple indications in nine markets across the APAC region.
- 09/23/2024
|
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
- Karyopharm Therapeutics (KPTI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 09/05/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , Sept. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 22,050 restricted stock units (RSUs) to five newly-hired employees.
- 09/03/2024
|
Karyopharm to Participate at Upcoming Investor Conferences
- NEWTON, Mass. , Sept. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies , today announced that the Company's senior management team will participate in the following investor conferences in September: H.C.
- 09/03/2024
|
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago.
- 08/06/2024
|
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
- – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million; Positive Momentum ex-US with Continued Regulatory and Reimbursement Approvals – – Updated Clinical Results at ASCO Annual Meeting Showed Median Progression-Free Survival (PFS) of 28.4 Months in the TP53 Wild-Type Exploratory Subgroup and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type Exploratory Subgroup from Phase 3 SIENDO Study of Selinexor Maintenance Treatment in Advanced/Recurrent Endometrial Cancer – – Pre-Clinical Data Presented at the June 2024 European Hematology Association Meeting Support Selinexor's Mechanism of Action Targeting Multiple Oncogenic Pathways beyond JAK/STAT and Builds on the Compelling Clinical Data in Myelofibrosis – – Completed Significant Refinancing Transactions and Amended Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Readouts and Potential Approvals from the Company's Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – – Raises the Lower End of Full-Year 2024 Total Revenue Guidance to $145.0 Million to $160.0 Million and U.S. XPOVIO Net Product Revenue Guidance to $105.0 Million to $120.0 Million; Lowers Full Year 2024 R&D and SG&A Expense Guidance to $250.0 Million to $265.0 Million – NEWTON, Mass. , Aug. 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.
- 08/06/2024
|
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia
- XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. XPOVIO® has been approved for multiple indications in eight markets across the APAC region.
- 08/05/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , Aug. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 14,000 restricted stock units (RSUs) to four newly-hired employees.
- 08/01/2024
|
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
- -- Conference Call Scheduled for Tuesday, August 6, 2024, at 8:00 a.m. ET -- NEWTON, Mass.
- 07/31/2024
|
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
- - Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of XPOVIO® in China. - Results from the registrational SEARCH study in China showed that the overall response rate (ORR) among the 60 Chinese patients treated with XPOVIO® met the study's prespecified primary endpoint.
- 07/05/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , July 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 8,800 restricted stock units (RSUs) to three newly-hired employees.
- 07/01/2024
|
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
- - XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). - The approval of XPOVIO® by the NHIS in South Korea is the fourth national reimbursement in the Antengene markets after mainland of China, Australia and Singapore.
- 06/26/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , June 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 9,500 restricted stock units (RSUs) to three newly-hired employees.
- 06/03/2024
|
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
- Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type Exploratory Subgroups Q-TWiST, an Important Metric Assessing Both Quality and Quantity of Clinical Benefit, Suggests Improvement with Selinexor versus Placebo, which is Critical in the Maintenance Setting Company Highlights Additional Presentations in Endometrial Cancer and Myelofibrosis at ASCO 2024 NEWTON, Mass. , June 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated exploratory subgroup analyses from the SIENDO study (NCT03555422), in patients with advanced or recurrent TP53 wild-type endometrial cancer at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 06/01/2024
|
Karyopharm to Participate at the Jefferies Global Healthcare Conference
- NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m.
- 05/29/2024
|
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
- Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5.
- 05/23/2024
|
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
- NEWTON, Mass. , May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2024 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 15 at 9:30 a.m.
- 05/08/2024
|
Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Elhan Webb - Senior Vice President of Investor Relations Richard Paulson - President & Chief Executive Officer Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - Chief Financial Officer Conference Call Participants Chris Raymond - Piper Sandler Maurice Raycroft - Jefferies Colleen Kusy - Baird Brian Abrahams - RBC Capital Markets Ed White - H.C. Wainwright Jonathan Chang - Leerink Partners Operator Good morning.
- 05/08/2024
|
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
- – $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Million of New Convertible Notes due in 2029 and Warrants – – Issues New $100.0 Million Senior Secured Term Loan due in 2028 – – Repays Principal Portion and Amends Royalty Agreement with HealthCare Royalty – NEWTON, Mass. , May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today that it has entered into a series of financing transactions that will extend the Company's debt maturities into 2028 and 2029, well beyond the Company's planned Phase 3 data readouts in 2025.
- 05/08/2024
|
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
- – Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Readouts and Potential Approvals from the Company's Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – – Achieves First Quarter 2024 Total Revenue of $33.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $26.0 Million – – Reaffirms Full Year 2024 Total Revenue Guidance of $140 .0 Million to $160 .0 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $100 .0 Million to $120 .0 Million – – Invited to Present Updated Data from a Pre-Specified Exploratory Subgroup Analysis of the Phase 3 SIENDO Trial of Selinexor Maintenance Treatment in Patients with TP53 Wild-type Advanced/Recurrent Endometrial Cancer at 2024 ASCO Annual Meeting – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.
- 05/08/2024
|
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
- -- Conference Call Scheduled for Wednesday, May 8, 2024, at 8:00 a.m. ET -- NEWTON, Mass.
- 05/02/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , May 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 72,700 restricted stock units (RSUs) to five newly-hired employees.
- 05/01/2024
|
Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts
- Karyopharm Therapeutics Inc.'s selinexor is being featured in 7 presentations at ASCO. The company is also exploring selinexor's potential role in myelofibrosis, with two key trials planned. Karyopharm Therapeutics' cash position is a challenge, but success in any of their pivotal trials could be a game changer for selinexor's prospects.
- 04/30/2024
|
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
- Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates" NEWTON, Mass. , April 24, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO Annual Meeting) being held May 31 - June 4 in Chicago, IL.
- 04/24/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees.
- 04/01/2024
|
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
- NEWTON, Mass. , March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m.
- 03/06/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , March 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,250 restricted stock units (RSUs) to two newly-hired employees.
- 03/01/2024
|
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.43 per share a year ago.
- 02/29/2024
|
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
- – Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company's Guidance – – Top-Line Data Readouts from Three Pivotal Phase 3 Trials Evaluating Selinexor in Endometrial Cancer, Myelofibrosis and Multiple Myeloma Expected in 2025 – – Company Provides Full-Year 2024 Total Revenue Guidance of $140 Million to $160 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $100 Million to $120 Million ; Cash Runway to Late 2025 – – Conference Call Scheduled for Today at 8:00 a.m. ET — NEWTON, Mass.
- 02/29/2024
|
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
- While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
- 02/25/2024
|
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
- -- Conference Call Scheduled for Thursday, February 29, 2024, at 8:00 a.m. ET -- NEWTON, Mass.
- 02/22/2024
|
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
- Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/14/2024
|
Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
- Karyopharm Inc. has entered the realm of undervalued biotech stocks, making it a potential buying opportunity. The company's main drug, selinexor, is currently approved for the management of multiple myeloma and diffuse large B-cell lymphoma. Karyopharm is pursuing indications for myelofibrosis and endometrial cancer, with promising preliminary data and ongoing clinical trials.
- 02/05/2024
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 26,850 restricted stock units (RSUs) to seven newly-hired employees.
- 02/01/2024
|
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
- – Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial Cancer and Myelofibrosis – – Preliminary Unaudited Full Year 2023 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $146 Million and $112 Million, Respectively, Meeting Company's Guidance – – Potential for Selinexor to be a Novel Maintenance Treatment for Patients with TP53 Wild-Type Endometrial Cancer Further Strengthened with Long-Term Exploratory Subgroup Analyses from SIENDO Study; Recruitment Ongoing in the Company's Pivotal Phase 3 Study; Further Updates Planned to be Presented in 2024 – – Opportunity to Define a New Myelofibrosis Treatment Paradigm Based on the Encouraging Data Presented from the Phase 1 Study of Selinexor in Combination with Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis; Recruitment Ongoing in the Company's Pivotal Phase 3 Study; Further Updates Planned to be Presented in 2024 – – Expect Cash Runway into Late 2025 Supporting Company Through Multiple Potentially Value Generating Milestones – NEWTON, Mass. , Jan. 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2023 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2023 achievements and 2024 objectives.
- 01/08/2024
|
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
- NEWTON, Mass. , Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 42nd Annual J.P.
- 01/03/2024
|
Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call Transcript
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - CFO Conference Call Participants Maury Raycroft - Jefferies Colleen Kusy - Baird Operator Good morning. My name is Guru and I will be your conference operator today.
- 11/02/2023
|
Penny Stocks To Buy Now? 3 With Ratings Up To 1,742%
- In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts.
- 08/03/2023
|
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.62 per share a year ago.
- 08/02/2023
|
Why Is Karyopharm Therapeutics (KPTI) Stock Up 21% Today?
- Karyopharm Therapeutics (NASDAQ: KPTI ) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. The Food and Drug Administration (FDA) has granted fast-track designation to the development of selinexor.
- 07/18/2023
|
All You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to Buy
- Karyopharm Therapeutics (KPTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 07/05/2023
|
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
- NEWTON, Mass. , May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6 in Chicago, Illinois and the 2023 European Hematology Association (EHA) Hybrid Congress, being held June 8-11 in Frankfurt, Germany.
- 05/23/2023
|
Karyopharm Therapeutics, Inc. (KPTI) Q1 2023 Earnings Call Transcript
- Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Kevin Strang - Jefferies Colleen Kusy - Robert W. Baird Nicole Gabreski - Piper Sandler Eric Joseph - JPMorgan Operator Good morning.
- 05/06/2023
|
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.53 per share a year ago.
- 05/04/2023
|
Karyopharm Therapeutics: Expanding Beyond The Crowded Multiple Myeloma Market
- Shares are down 50% over the past year as fierce competition in the multiple myeloma space negatively impacts Xpovio's growth prospects. However, there is significant optionality via expansion opportunities into new indications, starting with relapsed/refractory MDS readout in the near term.
- 03/20/2023
|
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch
- Short squeeze penny stocks to watch. The post Best Penny Stocks To Buy?
- 03/10/2023
|
Karyopharm Therapeutics, Inc. (KPTI) Q4 2022 Earnings Call Transcript
- Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank Maurice Raycroft - Jefferies Nicole Gabreski - Piper Sandler & Co. Michael Ulz - Morgan Stanley Edward White - H.C. Wainwright & Co. Eric Joseph - JPMorgan Chase & Co. Operator Good day.
- 02/15/2023
|
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates
- Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -26.47% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/15/2023
|
Karyopharm: Recent Sell-Off Hits A New Buy Target
- Karyopharm is still reporting growth, but the market continues to punish KPTI to fresh 52-week lows. I take a look at the company's Q3 earnings report. XPOVIO delivered strong year-over-year growth with $32M, up from $26.7M in Q3 of last year, representing 20% growth year-over-year.
- 12/28/2022
|
Karyopharm Therapeutics Inc. (KPTI) Q3 2022 Earnings Call Transcript
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Elhan Webb - Senior Vice President-Investor Relations Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Mike Mason - Chief Financial Officer Conference Call Participants Kevin Strang - Jefferies Abi Gray - R.W. Baird Brian Abrahams - RBC Capital Markets Eric Joseph - JPMorgan Operator Good afternoon.
- 11/03/2022
|
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 19.64% and 3.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Karyopharm: Market Is Overlooking Growth
- Karyopharm's growth strategy has generated significant increases in total revenues, net product revenue growth, licensing revenue, and milestone revenue. Despite the progress, the market continues to punish KPTI. The company is focusing on XPOVIO to maximize growth in multiple myeloma while ensuring their clinical pipeline continues to make progress. I believe Karyopharm has plenty of room to grow.
- 10/07/2022
|
Best Penny Stocks To Buy: 4 Short Squeeze Stocks To Watch Now
- Penny stocks to buy: Here's what short interest traders think The post Best Penny Stocks To Buy: 4 Short Squeeze Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/08/2022
|
Why Karyopharm Therapeutics Inched Higher Today
- The company's second-quarter performance had some highlights, but investors might have been concerned about full-year guidance.
- 08/04/2022
|
Karyopharm Therapeutics, Inc. (KPTI) CEO Richard Paulson on Q2 2022 Results - Earnings Call Transcript
- Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Mike Mason - EVP, CFO & Treasurer Reshma Rangwala - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Peter Lawson - Barclays Mike Ulz - Morgan Stanley Colleen Kusy - Baird Eric Joseph - JP Morgan Ed White - H.C Faisal Khurshid - SVB Securities Operator Good morning, and welcome to the Karyopharm Therapeutics Q2 ‘22 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
- 08/04/2022
|
Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022
- -- Conference Call Scheduled for Thursday, August 4, 2022, at 8:00 a.m. ET -- NEWTON, Mass.
- 07/28/2022
|
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
- Biogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of.
- 06/15/2022
|
Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
- – Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable Tolerability with No Dose Limiting Toxicities and 75% of Evaluable Patients Demonstrating ≥35% Spleen Volume Reduction (SVR 35) at Week 12 – – FDA Grants Orphan Drug Designation for Selinexor for the Treatment of Myelofibrosis – – Exploratory Subgroup Analyses from SIENDO Trial in Patients with Endometrial Cancer Treated with Selinexor as Maintenance Therapy Identified p53 Wild-type as a Potentially Important Predictor of Efficacy, with 10-month PFS Improvement over Placebo; No Benefit Was Seen in Patients with p53 Mutant Tumors – NEWTON, Mass., May 26, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced promising initial data from a Phase 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis and subgroup analyses and molecular classification data from the SIENDO study evaluating selinexor in endometrial cancer.
- 05/26/2022
|
Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
- NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m.
- 05/10/2022
|
Karyopharm Therapeutics, Inc. (KPTI) CEO Richard Paulson on Q1 2022 Results - Earnings Call Transcript
- Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Michael Mason - EVP, CFO & Treasurer Reshma Rangwala - Chief Medical Officer Patricia Judson - SVP, Medical Strategy Conference Call Participants Maurice Raycroft - Jefferies Peter Lawson - Barclays Bank Michael Ulz - Morgan Stanley Faisal Khurshid - SVB Leerink Edward White - H.C. Wainwright & Co. Eric Joseph - JPMorgan Chase & Co. Colleen Kusy - Robert W.
- 05/05/2022
|
Karyopharm: Another 2 Year Wait For Data
- KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later.
- 05/05/2022
|
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
- -- Conference Call Scheduled for Thursday, May 5, 2022, at 8:30 a.m. ET -- NEWTON, Mass.
- 04/28/2022
|
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/25/2022
|
Karyopharm to Participate at the Barclays Global Healthcare Conference
- NEWTON, Mass. , March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Barclays Global Healthcare Conference.
- 03/09/2022
|
Why Are Karyopharm Shares Trading Lower Today
- Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an update on its supplemental New Drug Application submission based on the Phase 3 SIENDO study data of selinexor as front-line maintenance therapy following chemotherapy in advanced or recurrent endometrial cancer. The.
- 03/02/2022
|
Here's Why Karyopharm Therapeutics Is Sliding on Tuesday
- Investors aren't pleased with the surprise departure of the company's chief medical officer.
- 02/22/2022
|
Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates
- Primary endpoint of phase 3 SIENDO study met in which a statistically significant improvement of progression-free survival was observed in patients treated with selinexor over placebo.
- 02/19/2022
|
Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference
- NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.
- 02/11/2022
|
Why Karyopharm Therapeutics Stock Was a Winner on Wednesday
- An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotech's stock.
- 02/09/2022
|
Karyopharm Therapeutics (KPTI) CEO, Richard Paulson on Q 2021 Results - Earnings Call Transcript
- Karyopharm Therapeutics (KPTI) CEO, Richard Paulson on Q 2021 Results - Earnings Call Transcript
- 02/08/2022
|
Why Karyopharm Therapeutics Stock Is Falling Today
- Fourth-quarter sales of Xpovio were encouraging, but top-line results from another trial were a little disappointing.
- 02/08/2022
|
Why Earnings Season Could Be Great for Karyopharm (KPTI)
- Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/07/2022
|
Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS
- The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.
- 01/26/2022
|
Karyopharm to Present at B. Riley Securities Oncology Investor Conference
- NEWTON, Mass., Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B.
- 01/21/2022
|
Karyopharm, Menarini Ink Over $200M Licensing Pact For Selinexor In Europe, Other Territories
- Karyopharm Therapeutics Inc (NASDAQ: KPTI) and the Menarini Group entered an exclusive licensing agreement whereby Menarini will commercialize Karyopharm's Nexpovio (selinexor) in Europe and other key global territories. Under the agreement terms, Menarini received exclusive rights to commercialize Nexpovio for oncology indications in the European Union and other European countries, Latin America and other key countries.
- 12/21/2021
|
Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position
- Karyopharm Therapeutics reported their Q3 earnings with a beat on revenue and a slight miss on EPS. The company revealed that XPOVIO is making inroads into multiple myeloma. Despite the encouraging earnings, the ticker has been sucked into the small-cap sell-off. I am looking to take advantage of the discounted share price and reload my KPTI position.
- 12/04/2021
|
Implied Volatility Surging for Karyopharm (KPTI) Stock Options
- Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.
- 11/29/2021
|
4 Health Care Stocks For Your November 2021 Watchlist
- Could these health care stocks be buys on President Biden's latest vaccine mandate?
- 11/04/2021
|
Karyopharm Therapeutics (KPTI) Stock: Why The Price Surged Today
- The stock price of Karyopharm Therapeutics Inc (NASDAQ: KPTI) increased 37.37% today. This is why it happened.
- 11/03/2021
|
Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q3 2021 Results - Earnings Call Transcript
- Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.47% and 45.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2021
|
Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls
- Karyopharm Therapeutics has been on my watch list for several years. Sadly, my buy conditions never manifested for me to establish a position. Now I am looking for an entry. I believe Karyopharm's current valuation along with its upside potential will eventually bring in some buyers at these levels and hopefully inject some bullish sentiment around the ticker.
- 09/15/2021
|
Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China
- SHANGHAI and HONG KONG, Aug. 23, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that China's National Medical Products Administration has approved a Phase II study of selinexor (XPOVIO®) for the treatment of patients with myelofibrosis (MF). MF is a clonal bone narrow neoplasm which can emerge either as primary MF (PMF), polycythemia vera (PV) or essential thrombocythemia (ET).
- 08/23/2021
|
Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options
- Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.
- 08/20/2021
|
Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q2 2021 Results - Earnings Call Transcript
- Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
KPTI Stock Price Increases Over 7% Pre-Market: Why It Happened
- The stock price of Karyopharm Therapeutics Inc. (Nasdaq: KPTI) increased by over 7% pre-market. This is why it happened.
- 08/03/2021
|
Karyopharm Announces Upcoming Virtual Investor Conference Participation
- NEWTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate on a speaker panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference titled, "Building Back a Better Commercial Infrastructure – Selling in COVID Times" and participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference.
- 08/03/2021
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass., Aug. 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 74,600 shares of Karyopharm's common stock to 11 newly-hired employees, with a grant date of July 30, 2021.
- 08/02/2021
|
Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021
- NEWTON, Mass., July 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.
- 07/29/2021
|
SA Marketplace 2021 Top Idea Contest: Mid-Year Update
- At the mid-year mark, our contributors give updates on their picks.
- 07/23/2021
|
Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies
- SHANGHAI and HONG KONG , July 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for selinexor, a first-in-class XPO1 inhibitor, for three indications: in combination with bortezomib and dexamethasone (XVd), or in combination with dexamethasone (Xd) for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM); and as monotherapy in adult patients with relapsed and/or refractory diffuse large B-cell lymphoma (rrDLBCL), including DLBCL arising from follicular lymphoma, who have received at least two lines of systemic therapy. Antengene has submitted New Drug Applications (NDAs) for selinexor in multiple Asia Pacific markets including China, Australia, South Korea, and Singapore, and was granted Priority Review status by China's National Medical Products Administration (NMPA) and Orphan Drug Designation by the Ministry of Food and Drug Safety of South Korea (MFDS).
- 07/13/2021
|
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)
- SHANGHAI and HONG KONG, July 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, recently announced that China's National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for single agent selinexor, a first-in-class orally available Exportin 1 (XPO1) inhibitor, for the treatment of patients with myelofibrosis (MF) in China. MF is a clonal hematologic neoplasm which can emerge either as primary MF, polycythemia vera (PV) or essential thrombocythemia (ET)[1].
- 07/05/2021
|
Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million
- NEWTON, Mass., June 24, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC (HCR) for up to $100 million in new financing to support the ongoing development and commercialization of XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and for the clinical development of Karyopharm's other programs, including eltanexor.
- 06/24/2021
|
Karyopharm: Why Is It Down, And What Should Take It Back Up
- I list 8 potential reasons the stock is down despite approvals. SIENDO is a major binary event for the stock.
- 06/23/2021
|
Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder
- Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced updated data from Phase 1/2 trial of eltanexor (ATG-016) for patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS). Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
- 06/09/2021
|
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress
- NEWTON, Mass., June 9, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming European Hematology Association (EHA) 2021 Virtual Congress taking place June 9-17, 2021.
- 06/09/2021
|
Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS
- --Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 8, 2021 /PRNewswire/ -- Antengene's Partner, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), announced updated data of eltanexor for the treatment of patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. This Phase I/II study evaluated single-agent eltanexor in patients with higher-risk MDS, ie, high-risk or intermediate-2 MDS by the International Prognostic Scoring System (IPSS) and 5%-19% myeloblasts.
- 06/08/2021
|
Karyopharm Announces Key Changes to Its Commercial Leadership Team
- NEWTON, Mass., June 8, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced key management changes to its commercial organization, including the appointment of Sohanya Cheng, MBA, as Senior Vice President of Sales and Commercial Operations.
- 06/08/2021
|
Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
- NEWTON, Mass., June 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on May 26, 2021 the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization for NEXPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
- 06/02/2021
|
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
- NEWTON, Mass., May 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.
- 05/19/2021
|
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
- Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China.
- 05/16/2021
|
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
- SHANGHAI and HONG KONG, May 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor (XPOVIO®) in the treatment of advanced or recurrent endometrial cancer (the SIENDO trial). Endometrial cancer is a common gynecologic malignancy which frequently occurs in women of reproductive age.
- 05/12/2021
|
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
- SHANGHAI and HONG KONG, May 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese Society of Clinical Oncology (CSCO), the most prominent organization in oncology in China, added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines (CSCO Guidelines) for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: (i) selinexor plus dexamethasone; and (ii) selinexor plus dexamethasone plus bortezomib; and (iii) selinexor plus dexamethasone plus pomalidomide for the treatment of relapsed myeloma.
- 05/05/2021
|
Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q1 2021 Results - Earnings Call Transcript
- Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q1 2021 Results - Earnings Call Transcript
- 05/03/2021
|
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates
- Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.00% and -12.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/03/2021
|
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
- NEWTON, Mass., May 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021.
- 05/03/2021
|
Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO® (selinexor) in Combination with Velcade® (bortezomib) and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma
- NEWTON, Mass., April 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Company's Type II Variation Marketing Authorization Application (MAA), which seeks to expand the currently authorized indication for NEXPOVIO® in the European Union to include, in combination with Velcade® (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- 04/26/2021
|
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology
- NEWTON, Mass., April 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that health-related quality of life (HRQoL) data from the Phase 3 portion of the SEAL ( Se linexor in A dvanced L iposarcoma) study were published online in Future Oncology.
- 04/19/2021
|
Revisiting Karyopharm Therapeutics
- Today, we revisit Karyopharm Therapeutics, a small oncology concern. The shares are off some 35% in 2021, despite the company continuing to execute well.
- 04/09/2021
|
Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings
- The National Medical Products Administration (NMPA) has approved Antengene Corporation Limited's Investigational New Drug Application for a Phase 1 trial of ATG-019 in China. The trial will evaluate the safety and tolerability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
- 04/06/2021
|
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- SHANGHAI and HONG KONG, April 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase I clinical trial to evaluate safety and toler ability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL) in China. As an orally bioavailable dual PAK4/NAMPT inhibitor, ATG-019 can lead to antitumor effects through energy depletion, inhibition of DNA repair, cell cycle arrest, inhibition of proliferation, and ultimately cell apoptosis.
- 04/05/2021
|
Karyopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood Cancer
- The European Commission has granted conditional marketing authorization for Karyopharm Therapeutics Inc's (NASDAQ: KPTI) Nexpovio (selinexor) for multiple myeloma. The approval covers Nexpovio combined with dexamethasone for multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
- 03/29/2021
|
Karyopharm Stock: Rationale For Bullishness
- Karyopharm Stock: Rationale For Bullishness
- 03/12/2021
|
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA
- SHANGHAI and HONG KONG, Feb. 23, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology...
- 02/23/2021
|
Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q4 2020 Results - Earnings Call Transcript
- Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q4 2020 Results - Earnings Call Transcript
- 02/11/2021
|
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates
- Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.72% and -0.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/11/2021
|
Karyopharm: Strong Potential, Low Price, Looks Investible
- KPTI is doing well with selinexor, with additional approvals and increasing sales. There are additional label expansions in the offing.
- 02/07/2021
|
Reddit playing a major role in biotech trading action, says Jefferies top health care analyst
- Jared Holz, Jefferies managing director and healthcare sector specialist, on which biotech stocks could be the next targets. With Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman and Brian Kelly.
- 02/04/2021
|
Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
- NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a...
- 01/29/2021
|
Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma
- Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.
- 12/21/2020
|
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
- NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor), the Company's...
- 12/18/2020
|
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
- NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN) added three different XPOVIO® (selinexor)...
- 12/11/2020
|
Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting
- NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation highlighting data related to XPOVIO® (selinexor), the Company's first-in-class, oral...
- 12/07/2020
|
Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting
- NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that over twenty presentations related to XPOVIO® (selinexor), the Company's first-in-class, oral Selective...
- 12/07/2020
|
Top Wall Street analysts are betting on these stocks heading into December
- TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Anaplan and Autodesk
- 11/29/2020
|
Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting
- NEWTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will present positive results from the Phase 3 portion of the randomized, double blind, placebo...
- 11/20/2020
|
Karyopharm Is Extremely Cheap After Recent Sell-Off
- Xpovio is showing good uptake after about a year on the market. The second line multiple myeloma indication will likely be added next Spring.
- 11/16/2020
|
Karyopharm Therapeutics: Current Share Price Under-Reflects The Inherent Value
- Recent advancements in readouts for Xpovio and Selinexor have yet to be reflected in market pricing, in our view. Karyopharm has had an in line quarter, where Xpovio sales were driven by new prescriber accounts and upward trends in average refill rate.
- 11/13/2020
|
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
- NEWTON, Mass., Nov. 12, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the Phase 3 BOSTON (Bortezomib, Selinexor and Dexamethasone) study evaluating XPOVIO...
- 11/12/2020
|
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting
- NEWTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twenty-one abstracts have been selected for virtual presentation, including two oral presentations, at...
- 11/04/2020
|
Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Earnings Call Transcript
- Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Earnings Call Transcript
- 11/02/2020
|
Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Quick Version Earnings Call Transcript
- Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Quick Version Earnings Call Transcript
- 11/02/2020
|
Karyopharm Therapeutics: Q3 Earnings Insights
- Shares of Karyopharm Therapeutics (NASDAQ:KPTI) increased 10.3% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 8.96% over the past year to ($0.73), which missed the estimate of ($0.72).
- 11/02/2020
|
Apple Is Evaluating Scratch-Resistant Diamond Like Coatings On Gorilla Glass (NASDAQ:AAPL)
- Apple is evaluating methods to strengthen further its display Gorilla Glass by coating them with diamonds.
- 10/07/2020
|
Week In Review: Antengene Approved By Hong Kong Exchange For $200 Million IPO
- Antengene, a three-year old Shanghai startup originally backed by Celgene, will conduct a Hong Kong IPO that is expected to raise $200 million.
- 08/30/2020
|
Oncology Stocks Area Trading Materially Lower The Last 2 Months
- Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.
- 08/24/2020
|
Kaskela Law LLC Announces Investigation of Karyopharm Therapeutics Inc. (KPTI) and Encourages Long-Term Stockholders to Contact the Firm
- Kaskela Law LLC announces that it is investigating Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) on behalf of the Company's stockholders. The investigation seeks to determine whether the members of Karyopharm's board of directors breached their fiduciary duties to the Company and its stockholders.
- 08/10/2020
|
Karyopharm Therapeutics Inc (KPTI) Q2 2020 Earnings Call Transcript
- This is Ian Karp and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Dr. Sharon Shacham, President and Chief Scientific Officer; Mr. Mike Mason, Chief Financial Officer; Mr. John Demaree, Chief Commercial Officer; and Mr. Christopher Primiano, Chief Business Officer and General Counsel. On the call today, Michael and John will provide an overview of key recent corporate developments and an update on our commercial progress and then Mike Mason will highlight the second quarter 2020 financial results.
- 08/05/2020
|
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
- Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.53% and 19.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2020
|
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor), and provided an overview of its key clinical development programs.
- 08/04/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 27,300 shares of Karyopharm's common stock to three newly-hired employees, with a grant date of July 31, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
- 08/03/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Top Small Cap Stocks for August 2020
- Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe. Small Cap stocks, as represented by the Russell 2000 Index (RUT), have underperformed the broader market, providing investors with a total return of -4.6% compared to the S&P 500's total return of 8.9% over the past 12 months. These market performance numbers and the statistics in the tables below are as of July 28.
- 07/29/2020
|
Does Karyopharm Therapeutics (NASDAQ:KPTI) Have A Healthy Balance Sheet?
- Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- 07/29/2020
|
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/28/2020
|
Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020
- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on Tuesday, August 4, 2020. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Tuesday, August 4, 2020, to discuss the financial results and other company updates.
- 07/28/2020
|
Were Hedge Funds Right About Souring On Karyopharm Therapeutics Inc (KPTI)?
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
- 07/28/2020
|
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
- NEWTON, Mass., July 20, 2020 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug.
- 07/20/2020
|
Personal assistant, 21,pleads not guilty to murdering tech CEO boss
- Tyrese Haspil, 21, has pleaded not guilty to a charge of 2nd-degree murder after he was arrested and accused of decapitating and dismembering his boss Fahim Saleh.
- 07/20/2020
|
Karyopharm Is Trading At A Discount After Recent Additional Xpovio Approval
- Karyopharm has a market cap under $1.5 billion, yet peak sales of Xpovio in just its first 3 indications could easily exceed that figure.
- 07/19/2020
|
Fahim Saleh murder suspect 'had difficult childhood' but not violent, aunt says
- THE accused killer of a tech millionaire found butchered and stuffed into bags had a difficult childhood but isn’t violent or incapable of murder, his aunt has said. Tyrese Devon Haspi pleade…
- 07/19/2020
|
Personal assistant accused of killing his boss had troubled childhood
- Tyrese Haspil, 21, was arrested on Friday and charged with the grisly murder of his boss Fahim Saleh. Haspil's aunt Marjorie Sine expressed her shock over the allegations against him.
- 07/19/2020
|
Karyopharm's XPOVIO Progress And Other News: The Good, Bad And Ugly Of Biopharma
- Karyopharm collaborates with National Cancer Institute for XPOVIO. ADC Therapeutics advances LOTIS 3 Clinical Trial of Loncastuximab Tesirine.
- 07/19/2020
|
Advisor Group Holdings Inc. Makes New $333,000 Investment in Karyopharm Therapeutics Inc (NASDAQ:KPTI)
- Advisor Group Holdings Inc. bought a new position in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,368 shares of the company’s stock, valued at approximately $333,000. Other hedge funds have also […]
- 07/18/2020
|
Karyopharm Therapeutics Inc Expected to Earn Q2 2020 Earnings of ($0.48) Per Share (NASDAQ:KPTI)
- Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Investment analysts at SVB Leerink decreased their Q2 2020 earnings per share estimates for shares of Karyopharm Therapeutics in a report issued on Tuesday, July 14th. SVB Leerink analyst J. Chang now forecasts that the company will post earnings per share of ($0.48) for the quarter, down from their previous […]
- 07/18/2020
|
Karyopharm Therapeutics (KPTI) Received its Third Buy in a Row - Markets
- After RBC Capital and Canaccord Genuity gave Karyopharm Therapeutics (NASDAQ: KPTI) a Buy rating last month, the company received another
- 07/17/2020
|
Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research
- NEWTON, Mass., July 17, 2020 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative.
- 07/17/2020
|
Wells Fargo & Company MN Has $1.22 Million Stock Holdings in Karyopharm Therapeutics Inc (NASDAQ:KPTI)
- Wells Fargo & Company MN lifted its position in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 3.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,409 shares of the company’s stock after acquiring an additional 1,984 shares during the period. Wells Fargo & Company […]
- 07/15/2020
|
Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor) | MarketScreener
|
Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)
- \-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the Second Quarter 2020 --\-- Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch --NEWTON, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced preliminary unaudited second quarter 2020 net product sales for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and provided additional updates on XPOVIO’s commercial results.Oral XPOVIO tablets became commercially available to patients with relapsed or refractory multiple myeloma in the U.S. in July 2019. Based on preliminary unaudited financial information, Karyopharm expects net product sales of XPOVIO to be approximately $18.5 million during the second quarter 2020 representing an approximate 15% increase in net product sales compared to the first quarter of 2020. Despite COVID-19-related operational challenges, which included the diversion of physician and other healthcare resources to manage the ongoing COVID-19 pandemic and the significant reduction in Karyopharm’s field force in-person activities, XPOVIO sales grew as a result of an increasing demand from both academic and community-based physicians. Additionally, prescription refill rates, as well as the average number of prescriptions per patient, continued to grow during the quarter, further reinforcing the positive experience that Karyopharm believes many patients are having with XPOVIO treatment.“While no company is immune to the challenges of the ongoing global COVID-19 pandemic, we are very pleased to see demand for XPOVIO increase during this most recent quarter,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. “In addition to encouraging preliminary second quarter sales, we are excited by the recent U.S. Food and Drug Administration’s accelerated approval of XPOVIO for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, as well as the recently presented positive results from the Phase 3 BOSTON study in patients with multiple myeloma following one to three prior lines of therapy. We are proud to be making such an important impact for patients battling relapsed or refractory disease and look forward to providing the investment community with additional details of our recent achievements when we report our unaudited financial results for the second quarter in early August 2020.”The financial information presented in this press release may be adjusted as a result of the completion of the customary quarterly review process, and the Company’s actual financial results may differ from the preliminary estimated financial information set forth above. As there remains significant uncertainty surrounding the overall market implications driven by the ongoing COVID-19 pandemic, Karyopharm is announcing preliminary unaudited sales results for the second quarter 2020 to increase transparency to the investment community during these unique times. Additionally, Karyopharm does not expect to regularly announce preliminary unaudited sales information in each subsequent quarter.About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion. Karyopharm received accelerated U.S. Food and Drug Administration (FDA) approval of XPOVIO in July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Karyopharm has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with a request for conditional approval of selinexor in this same RRMM indication. Karyopharm submitted a supplemental New Drug Application (sNDA) to the FDA requesting an expansion of its current indication to include the treatment for patients with multiple myeloma after at least one prior line of therapy based on the positive results from the Phase 3 BOSTON study which evaluated selinexor in combination with Velcade® (bortezomib) and low-dose dexamethasone. In June 2020, Karyopharm received accelerated FDA approval of XPOVIO for its second indication in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple cancer indications, including as a potential backbone therapy in combination with approved myeloma therapies (STOMP), in liposarcoma (SEAL) and in endometrial cancer (SIENDO), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with approved therapies in a variety of tumor types to further inform Karyopharm’s clinical development priorities for selinexor. Additional clinical trial information for selinexor is available at www.clinicaltrials.gov.IMPORTANT SAFETY INFORMATIONThrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma (MM) and developed or worsened in patients with DLBCL.Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.Neutropenia: XPOVIO can cause life-threatening neutropenia, potentially increasing the risk of infection. Neutropenia and febrile neutropenia occurred in patients with MM and in patients with DLBCL.Obtain white blood cell counts with differential at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Monitor patients for signs and symptoms of concomitant infection and evaluate promptly. Consider supportive measures, including antimicrobials and growth factors (e.g., G-CSF). Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction (AR).Gastrointestinal Toxicity: XPOVIO can cause severe gastrointestinal toxicities in patients with MM and DLBCL.Nausea/Vomiting: Provide prophylactic antiemetics. Administer 5-HT3 receptor antagonists and other anti-nausea agents prior to and during treatment with XPOVIO. Interrupt, reduce dose, or permanently discontinue based on severity of ARs. Administer intravenous fluids to prevent dehydration and replace electrolytes as clinically indicated.Diarrhea: Interrupt, reduce dose, or permanently discontinue based on severity of ARs. Provide standard anti-diarrheal agents, administer intravenous fluids to prevent dehydration, and replace electrolytes as clinically indicated.Anorexia/Weight Loss: Monitor weight, nutritional status, and volume status at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Interrupt, reduce dose, or permanently discontinue based on severity of ARs. Provide nutritional support, fluids, and electrolyte repletion as clinically indicated.Hyponatremia: XPOVIO can cause severe or life-threatening hyponatremia. Hyponatremia developed in patients with MM and in patients with DLBCL.Monitor sodium level at baseline and throughout treatment. Monitor more frequently during the first 2 months of treatment. Correct sodium levels for concurrent hyperglycemia (serum glucose >150 mg/dL) and high serum paraprotein levels. Assess hydration status and manage hyponatremia per clinical guidelines, including intravenous saline and/or salt tablets as appropriate and dietary review. Interrupt, reduce dose, or permanently discontinue based on severity of the AR.Serious Infection: XPOVIO can cause serious and fatal infections. Most infections were not associated with Grade 3 or higher neutropenia. Atypical infections reported after taking XPOVIO include, but are not limited to, fungal pneumonia and herpesvirus infection.Monitor for signs and symptoms of infection, and evaluate and treat promptly.Neurological Toxicity: XPOVIO can cause life-threatening neurological toxicities.Coadministration of XPOVIO with other products that cause dizziness or mental status changes may increase the risk of neurological toxicity.Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, until the neurological toxicity fully resolves. Optimize hydration status, hemoglobin level, and concomitant medications to avoid exacerbating dizziness or mental status changes. Institute fall precautions as appropriate.Embryo-Fetal Toxicity: XPOVIO can cause fetal harm when administered to a pregnant woman.Advise pregnant women of the potential risk to a fetus.
- 07/14/2020
|
-$0.56 EPS Expected for Karyopharm Therapeutics Inc (NASDAQ:KPTI) This Quarter
- Brokerages expect that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will post earnings per share of ($0.56) for the current quarter, according to Zacks. Six analysts have made estimates for Karyopharm Therapeutics’ earnings, with estimates ranging from ($0.67) to ($0.47). Karyopharm Therapeutics posted earnings of ($0.71) per share during the same quarter last year, which suggests a positive […]
- 07/13/2020
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 41,700 shares of Karyopharm’s common stock to eight newly-hired employees, with a grant date of June 30, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $18.94 per share, the closing price of Karyopharm’s common stock on June 30, 2020.
- 07/01/2020
|
2 Biotech Stocks That Could Soar in 2020 | The Motley Fool
- These companies offer promising pipelines that could deliver in the long term.
- 07/01/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on G1 Therapeutics
- 07/01/2020
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NEWTON, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today...
- 07/01/2020
|
Karyopharm Therapeutics : XPOVIO, FDA Approved for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma, Available at Biologics by McKesson | MarketScreener
|
7 ans de prison pour inceste avec séquestration sur sa demi-soeur
- Il a imposé une relation sexuelle de force, avec violence, menace et séquestration à la victime
- 06/30/2020
|
Top Small Cap Stocks for July 2020
- Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe. Small cap stocks, as represented by the Russell 2000 Index (RUT), have underperformed the broader market over the past 12 months.
- 06/29/2020
|
McKesson : XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Available at Biologics by McKesson | MarketScreener
|
Rhythm's Setmelanotide Data And Other News: The Good, Bad And Ugly Of Biopharma
- Rhythm reports positive Setmelanotide data. Biohaven’s Troriluzole flops in late stage study. Karyopharm's XPOVIO receives approval.
- 06/28/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (NASDAQ: DVAX) and BELLUS Health (NASDAQ: BLU) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dynavax (DVAX
- 06/26/2020
|
Analysts Offer Insights on Healthcare Companies: Chimerix (NASDAQ: CMRX) and BerGenBio AS (Other OTC: BRRGF) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chimerix (CMRX
- 06/26/2020
|
2020 Insights into the Global Multiple Myeloma Market and Competitive Landscape - ResearchAndMarkets.com
|
Pedidos de seguro-desemprego sobem 35% na 1ª quinzena de junho e somam 3,6 milhões em 2020
- Levantamento foi divulgado hoje pela Secretaria de Trabalho
- 06/25/2020
|
Brokers Issue Forecasts for Karyopharm Therapeutics Inc’s Q2 2020 Earnings (NASDAQ:KPTI)
- Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Equities researchers at SVB Leerink lifted their Q2 2020 EPS estimates for shares of Karyopharm Therapeutics in a research note issued on Monday, June 22nd. SVB Leerink analyst J. Chang now forecasts that the company will earn ($0.47) per share for the quarter, up from their prior forecast of ($0.48). […]
- 06/25/2020
|
HC Wainwright Increases Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $41.00
- Karyopharm Therapeutics (NASDAQ:KPTI) had its target price hoisted by HC Wainwright from $40.00 to $41.00 in a research report issued on Tuesday, BenzingaRatingsTable reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 120.91% from the company’s current price. Several other research firms have also […]
- 06/25/2020
|
|
|
XPOVIO® (selinexor) Now Approved for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Available from Onco360
|
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating XPOVIO in patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) were published online in The Lancet Haematology. The SADAL study evaluated selinexor, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound for the treatment of adult patients with RR DLBCL, not otherwise specified, who have received at least two prior therapies. “The clinical outcomes for patients with heavily pretreated relapsed or refractory DLBCL are typically very poor, and hence results from the multinational Phase 2b SADAL study are noteworthy,” said Prof Nagesh Kalakonda, University of Liverpool, lead author of the manuscript.
- 06/24/2020
|
Karyopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor Opportunity
- Xpovio is anticipated to become a blockbuster multiple myeloma MM treatment, and real-world data demonstrate strong market uptake thus far. 2Q sales should exce
- 06/24/2020
|
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Increased to $26.00 by Analysts at Wedbush
- Karyopharm Therapeutics (NASDAQ:KPTI) had its price target increased by Wedbush from $18.99 to $26.00 in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. They currently have a neutral rating on the stock. A number of other research firms also recently weighed in on KPTI. Royal Bank of Canada reissued a buy rating […]
- 06/24/2020
|
XPOVIO® (selinexor) Now Approved for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Available from Onco360
- Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Karyopharm to be a specialty pharmacy partner for XPOVIO® (selinexo
- 06/24/2020
|
Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL
- Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.
- 06/23/2020
|
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Pfizer (NYSE: PFE) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics
- 06/23/2020
|
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Genocea Biosciences (NASDAQ: GNCA) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics
- 06/23/2020
|
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
- 06/23/2020
|
KARYOPHARM THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIO® (selinexor), the Company’s first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. This indication was approved based on response rate under the FDA’s Accelerated Approval Program, which was developed to allow for expedited approval of drugs that treat serious conditions and that fill an unmet medical need.
- 06/22/2020
|
Pedidos de seguro-desemprego sobem 43% em maio no Amapá; são mais de 2,2 mil na pandemia
- Benefício pode ser requerido por trabalhadores dispensados sem justa causa.
- 06/22/2020
|
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
- Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals for Merck & Co., Inc. (NYSE: MRK) and Novartis AG (NYSE: NVS), among others. The week also witnessed a flurry of activity on the IPO front.The following are key biotech catalysts for the unfolding week.Conferences * American Association of Cancer Research, or AACR, Virtual Annual Meeting II: June 22-24 * BMO 2020 Prescriptions for Success Healthcare Conference: June 23 * American Thoracic Society, or ATS 2020 Virtual: Clinical Trials Session: June 24 * BofA Securities Napa Biopharma Conference: June 24 * Cowen FutureHealth Conference: June 24-25PDUFA Dates The FDA is scheduled to rule on Karyopharm Therapeutics Inc's (NASDAQ: KPTI) sNDA for Selinexor, which could expand the drug's label to include adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who have received at least two prior therapies. (Tuesday)Zogenix, Inc.'s (NASDAQ: ZGNX) NDA for Fintepla as a potential treatment candidate for seizures associated with Dravet syndrome is pending before the FDA, with the regulatory agency expected to rule on the drug by the June 25 PDUFA date.Heron Therapeutics Inc (NASDAQ: HRTX) awaits an FDA nod for its HTX-011 as a treatment option for post-operative pain. (Friday)The FDA is also expected to rule on Chiasma Inc's (NASDAQ: CHMA) NDA for Mycapssa, which is being evaluated as a maintenance therapy for acromegaly. (Friday)Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has a PDUFA date of June 26 for its NDA for NASH drug candidate obeticholic acid. An Adcom meeting scheduled for June 9 has been postponed, making it less likely an approval comes through by the PDUFA date.View more earnings on IBBSee Also: Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'Clinical Readouts AACR Presentations VBI Vaccines Inc (NASDAQ: VBIV) is due to present expanded immunologic and tumor response data from the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma patients. (Monday)BioNTech SE - ADR (NASDAQ: BNTX) will present data from the Phase 1 trial of BNT122 in multiple solid tumors.DelMar Pharmaceuticals Inc (NASDAQ: DMPI) is due to present data from separate Phase 2 trials of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma as well as in patients with MGMT-unmethylated, bevacizumab-naive glioblastoma in the recurrent or adjuvant setting.Affimed NV (NASDAQ: AFMD) is scheduled to present two posters, one on AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies, and another on preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma.Presentations At ATS 2020 Virtual: Clinical Trials Session AstraZeneca plc (NYSE: AZN): Phase 3 ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pulmonary disease. Insmed Incorporated (NASDAQ: INSM): Phase 2 WILLOW study evaluating the efficacy, safety and pharmacokinetics of INS1007 administered once daily in adults with non-cystic fibrosis bronchiectasis.United Therapeutics Corporation (NASDAQ: UTHR): key data from the INCREASE study of Tyvaso inhalation solution in patients suffering from WHO Group 3 pulmonary hypertension associated with interstitial lung disease. Related Link: Novavax Beefs Up Executive Team As It Sprints In The Coronavirus Vaccine RaceOther Presentations Aridis Pharmaceuticals Inc (NASDAQ: ARDS) will participate in a Cantor Fitzgerald-hosted Virtual Fireside Chat on Thursday. The discussion is intended to provide a comprehensive profile of the company's CRISPR-based platform technology APEX, with a particular emphasis on addressing how it can be rapidly customized to future COVID strains as well as any emerging viral or bacterial pathogens.Earnings * Affimed (Tuesday, before the market open) * Aethlon Medical, Inc. (NASDAQ: AEMD) (Thursday, after the close)See more from Benzinga * The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs * The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/21/2020
|
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
- Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals...
- 06/21/2020
|
Stocks To Watch: Nike, Apple, Ford And Stressed Banks
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 06/20/2020
|
Karyopharm Therapeutics (NASDAQ:KPTI) Rating Increased to Hold at BidaskClub
- Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports. Several other research analysts also recently commented on KPTI. Royal Bank of Canada reaffirmed a “buy” rating and set a $28.00 target price on shares of […]
- 06/19/2020
|
Karyopharm Therapeutics Inc (KPTI): Hedge Funds Taking Some Chips Off The Table
- In this article you are going to find out whether hedge funds think Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
- 06/18/2020
|
In Africa, those who beat the virus continue to live under its cloud
- Kinshasa, DR Congo | AFP | As coronavirus cases accelerate in Africa, those who recover from the virus find that their struggle is not over as denial of the disease and stigmatisation run deep across the continent. People who have been treated for COVID-19 say they are ostracised in their communities, are discouraged from going to …
- 06/18/2020
|
In Africa, those who beat coronavirus continue to live under its cloud - Vanguard News
- As coronavirus cases accelerate in Africa, those who recover from the virus find that their struggle is not over as denial of the disease and stigmatisation run deep across the continent. People who have been treated for COVID-19 say they are ostracised in their communities, are discouraged from going to hospital, and face constant suspicionRead More
- 06/18/2020
|
In Africa, those who beat the virus continue to live under its cloud - France 24
- In Africa, those who beat the virus continue to live under its cloud
- 06/18/2020
|
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), IDEAYA Biosciences (NASDAQ: IDYA) and Neurocrine (NASDAQ: NBIX) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bausch Health
- 06/17/2020
|
Karyopharm Brain Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:KPTI)
- Karyopharm doses first patient in a phase 1/2 brain cancer trial. Dynavax completes enrolment for phase 1 clinical trial of Heplisav-B. BeyondSpring reports pos
- 06/15/2020
|
Analysts Are Bullish on These Healthcare Stocks: Magenta Therapeutics (MGTA), Viela Bio (VIE) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Magenta Therapeutics
- 06/15/2020
|
Edited Transcript of KPTI earnings conference call or presentation 5-May-20 12:30pm GMT
- Q1 2020 Karyopharm Therapeutics Inc Earnings Call
- 06/12/2020
|
Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting
- NEWTON, Mass., June 12, 2020 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that eight posters relating to XPOVIO®.
- 06/12/2020
|
Govt To Invest In 52 Startups Providing Covid-19 Healthcare Solutions
- Indian government, through its CAWACH initiative, has is looking to invest in 52 startups developing solutions to tackle Covid-19 pandemic.
- 06/11/2020
|
Small Caps Build Steam And Biotechs Remain Well-Positioned
- Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re
- 06/10/2020
|
Karyopharm Starts Dosing in Selinexor Study for Glioblastoma
- Karyopharm (KPTI) commences a phase I/II study evaluating Xpovio (selinexor) in combination with standard-of-care therapy in patients with newly-diagnosed or recurrent glioblastoma.
- 06/10/2020
|
Pedidos de seguro-desemprego somam 960.258 em maio, com alta de 53%
- Com a crise econ
- 06/09/2020
|
Seguro-desemprego: país tem 960 mil pedidos em maio; total durante pandemia vai a 1,9 milhão
- Números foram divulgados nesta terça-feira pelo Ministério da Economia. Desde o início da pandemia do novo coronavírus, quase 2 milhões de pessoas pediram o seguro-desemprego.
- 06/09/2020
|
Karyopharm Therapeutics Reports Dosing Of First Patient In Phase 1/2 Study Of Selinexor In Combo With Standard Of Care Therapy For Patients With Newly Diagnosed, Recurrent Glioblastoma
|
Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard of care therapy in patients with newly diagnosed or recurrent glioblastoma (GBM). Selinexor is an oral selective inhibitor of nuclear export (SINE) compound which blocks the cellular protein XPO1, whose function includes playing a key role in regulating the activity of tumor suppressor proteins and other oncoproteins relevant in cancer cell biology. XPO1 may be an important, novel target in the treatment of patients with GBM as it is frequently overexpressed in both GBM and in high-grade gliomas, and the degree of XPO1 over-expression correlates with higher tumor grade and poor overall patient survival.
- 06/09/2020
|
[Funding alert] PadUp mentee Ameliorate Biotech raises Rs 2 Cr in angel round
- The Bengaluru-based startup has received funding from Friends of PadUp, Villgro USA, Vinners, LetsVenture, SINE IIT Bombay, and DERBI. Funds will be used to conclude clinical trials efficiently, and for commercialisation of the product.
- 06/09/2020
|
What is Fourier Series? and It’s beauty
|
Are Options Traders Betting on a Big Move in Karyopharm Therapeutics (KPTI) Stock?
- Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.
- 06/03/2020
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,800 shares of Karyopharm’s common stock to seven newly-hired employees, with a grant date of May 29, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $18.49 per share, the closing price of Karyopharm’s common stock on May 29, 2020.
- 06/01/2020
|
Best Buy has tons of Apple deals and more today – here are the 10 best ones
- Best Buy’s sale is one of the best ways to start off June, with tons of great deals to be found on top-selling product from Apple and more. Here, we have rounded up 10 of the very best deals …
- 06/01/2020
|
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
- Despite the FDA tied up with COVID-19-related activities, May turned out to be a positive month for biopharma companies from the perspective of drug approvals. Three new molecular...
- 06/01/2020
|
Cidade do governador Zema, Arax
|
Top Small Cap Stocks for June 2020
- Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe. Small cap stocks, as represented by the Russell 2000 Index (RUT), have underperformed the broader market over the past 12 months.
- 05/29/2020
|
Lady Gaga 'Chromatica' available to stream and download now
- Lady Gaga's Chromatica is now available for stream and download from all major music services having dropped on 29 May 2020.
- 05/29/2020
|
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)( announced a collaboration study for razuprotafib in COVID-19 treatment) * Aileron Therapeutics Inc (NASDAQ: ALRN) * Arca Biopharma Inc (NASDAQ: ABIO) ( reacted to its planned foray into COVID-19 treatment) * argenx SE - ADR (NASDAQ: ARGX) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) * ChemoCentryx Inc (NASDAQ: CCXI) * GENMAB A/S/S ADR (NASDAQ: GMAB)(announced positive topline Phase 3 data for daratumumab in light-chain amyloidosis) * Imara Inc NASDAQ: (IMRA) * Liquidia Technologies Inc (NASDAQ: LQDA) * Mersana Therapeutics Inc (NASDAQ: MRSN) * Protagonist Therapeutics Inc (NASDAQ: PTGX) * Qiagen NV (NYSE: QGEN) * Tenax Therapeutics Inc (NASDAQ: TENX) * Turning Point Therapeutics Inc (NASDAQ: TPTX) * Vermillion, Inc. (NASDAQ: VRML)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 28) * Zafgen Inc (NASDAQ: ZFGN)Stocks In Focus Karyopharm to Present Positive Selinexor Data In Multiple Myeloma Patients At ASCO Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced detailed results from the pivotal Phase 3 BOSTON study that evaluated once-weekly selinexor in combination with once-weekly Velcade and low-dose dexamethasone, or SVd, compared to the standard twice-weekly Velcade plus low-dose dexamethasone, or Vd, in second-line to fourth-line setting in multiple myeloma patients. The data is to be presented at the ASCO 2020 Virtual Scientific Program.The SVd arm, according to the company, showed a statistically significant increase of 47% in median progression-free survival compared to the Vd arm. The overall response rate was 76.4% for the SVd arm compared to 62.3% for the Vd arm.The stock rose 7.71% to $20.25 in after-hours trading.Eisai, Merck Announce ASCO Presentations Eisai Co., Ltd (OTC: ESALY) and Merck & Co., Inc. (NYSE: MRK) said results from two trials evaluating the former's Lenvima, plus the latter's anti-PD-1 therapy Keytruda in patients with unresectable hepatocellular carcinoma, or HCC, with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma, or ccRCC, who progressed following immune checkpoint inhibitor therapy, respectively, showed tumor response.The data is to be presented at the ASCO Virtual Scientific Program.Separately, Merck said a Phase 3 trial, dubbed KEYNOTE-177, evaluating Keytruda for the first-line treatment of patients with microsatellite instability-high, or MSI-H, or mismatch repair deficient, or dMMR, unresectable or metastatic colorectal cancer showed Keytruda significantly reduced the risk of disease progression or death by 40%, with a median progression-free survival of 16.5 months compared with 8.2 months for patients treated with chemotherapy, a current standard of care.Merck said the data is scheduled to be presented Sunday in the ASCO meeting.Altimmune Shares Rally On Insider Buying Altimmune Inc (NASDAQ: ALT) shares were rallying after Venrock Healthcare Capital Partners III filed with the SEC in Form 4 a series of purchases made over this week that has taken its holdings to 3 million shares. A total of 1.304 million shares were accumulated over the week.Immutep Gets $2.41M In R&D; Tax Incentive From French Government IMMUTEP LTD/S ADR (NASDAQ: IMMP) said it has received a 2.174-million euro or $2.41 million, R&D; tax incentive payment in cash from the French government. The tax credit is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761, the company said.In after-hours trading, the stock added 2.40% to $1.28.Roche's Cancer Drug Gets Positive European Medicines Agency Committee Recommendation Roche Holdings AG (OTC: RHHBY) said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion under conditional marketing authorization for Rozlytrek for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase gene fusion. The CHMP has also recommended Rozlytrek for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer not previously treated with ROS1 inhibitors.Offerings Marinus Pharmaceuticals Inc (NASDAQ: MRNS) priced its underwritten public offering of 16 million shares at $2.50 per share, for generating gross proceeds of about $40 million. The company expects the offering to close on or about June 2.The stock slid 8.21% to $2.57 in after-hours trading.On The Radar Several companies are scheduled to present data on their pipeline assets in the ASCO 2020 Annual Meeting Virtual Scientific Program. Some of the companies presenting Friday include:• Arvinas Inc (NASDAQ: ARVN) • Trillium Therapeutics Inc (NASDAQ: TRIL) Cardiff Oncology Inc (NASDAQ: CRDF) • Iovance Biotherapeutics Inc (NASDAQ: IOVA) • Blueprint Medicines Corp (NASDAQ: BPMC) • Allogene Therapeutics Inc (NASDAQ: ALLO) • Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) • GENMAB A/S/S ADR (NASDAQ: GMAB) • AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) • Amgen, Inc. (NASDAQ: AMGN) • Clovis Oncology Inc (NASDAQ: CLVS) • IMMUTEP LTD/S ADR (NASDAQ: IMMP) • Heat Biologics Inc (NASDAQ: HTBX) • Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) • Oncolytics Biotech, Inc. (NASDAQ: ONCY) • Athenex Inc (NASDAQ: ATNX) • Harpoon Therapeutics Inc (NASDAQ: HARP) • Gossamer Bio Inc (NASDAQ: GOSS) • ImmunoGen, Inc (NASDAQ: IMGN) • Merus NV (NASDAQ: MRUS) • CytomX Therapeutics Inc (NASDAQ: CTMX) • Corvus Pharmaceuticals Inc (NASDAQ: CRVS) • Pfizer Inc. (NYSE: PFE) • CELYAD SA/ADR (NASDAQ: CYAD) • Immunomedics, Inc. (NASDAQ: IMMU) • Xencor Inc (NASDAQ: XNCR) • MacroGenics Inc (NASDAQ: MGNX) • DelMar Pharmaceuticals Inc (NASDAQ: DMPI) • Salarius Pharmaceuticals Inc (NASDAQ: SLRX) • AstraZeneca plc (NYSE: AZN) • Genocea Biosciences Inc (NASDAQ: GNCA) • NextCure Inc (NASDAQ: NXTC) • Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH) • Adaptimmune Therapeutics PLC (NASDAQ: ADAP) • ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) • Agios Pharmaceuticals Inc (NASDAQ: AGIO) • Oncternal Therapeutics Inc (NASDAQ: ONCT) • Roche • Aptose Biosciences Inc (NASDAQ: APTO) • Kura Oncology Inc (NASDAQ: KURA) • Innate Pharma SA (NASDAQ: IPHA) • Imv Inc (NASDAQ: IMV): • MEI Pharma Inc (NASDAQ: MEIP) • TapImmune Inc. common stock (NASDAQ: MRKR) • Inovio Pharmaceuticals Inc (NASDAQ: INO)See more from Benzinga * The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas * Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A; Deal Aimed At Treatment, Vaccine Development(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/29/2020
|
COVID-19 Drug and Vaccine Pipeline Status Report - Research; Pre-Clinical; Phase 1, 2 & 3 Drug Candidates - ResearchAndMarkets.com
|
Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
|
Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
- -- Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to.
- 05/28/2020
|
Karyopharm to Participate at Jefferies Virtual Healthcare Conference
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 9:30 a.m. ET. A live webcast of the fireside chat can be accessed on the "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the fireside chat.
- 05/26/2020
|
Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced it will host an investor conference call to discuss detailed results from the pivotal, Phase 3 BOSTON study evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. The conference call will follow the presentation of this data at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. As previously reported, the BOSTON study met its primary endpoint with a significant increase in progression-free survival in patients with multiple myeloma following one to three prior lines of therapy.
- 05/26/2020
|
Karyopharm Therapeutics: Getting Paid Well For Accepting Uncertainty (NASDAQ:KPTI)
- The rule should be a reward for risk involvement. Understood, but not always achieved. How to score better: Bigger, more often, fewer losses? When uncertainty c
- 05/22/2020
|
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Q1 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of Karyopharm Therapeutics Inc. - KPTI stock
- 05/21/2020
|
Karyopharm Therapeutics shares are trading higher after the company reported the submission of a supplemental New Drug Application to the FDA seeking approval for XPOVIO.
|
Karyopharm Therapeutics Reports Submission Of Supplemental New Drug Application For XPOVIO As Treatment For Patients With Multiple Myeloma After At Least One Prior Line Of Therapy
|
Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for XPOVIO® (selinexor), its first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with previously treated multiple myeloma. “Earlier this year, we reported positive top-line results from the pivotal Phase 3 BOSTON study evaluating the combination of XPOVIO (selinexor), once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) as a second line treatment for patients with relapsed or refractory multiple myeloma,” said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm.
- 05/20/2020
|
KPTI Has sNDAs In Process That Could More Than Double Its Share Price If Approved
- Xpovio's current label is 4th line Multiple Myeloma therapy (MM~6,000 patients/year). By 1/1/2021 Xpovio could be approved/labelled as 2nd/3rd line MM and 4th l
- 05/13/2020
|
Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19 pandemic including cancer patients, their families, and the healthcare workers caring for them. Karyopharm will donate masks to Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society®, three prominent organizations focused on the well-being of cancer patients, to improve the safety and security of the broader cancer community. As part of this initiative, Family Reach, a national 501(c)(3) organization dedicated to eradicating the financial barriers that accompany a cancer diagnosis through their Financial Treatment Program, will distribute masks to hospitals throughout Massachusetts.
- 05/13/2020
|
Procura pelo seguro-desemprego cai 28% em abril no AP; saiba como solicitar
- Buscas vão na contramão do dado nacional, que registrou alta de 22% na comparação com 2019. Benefício pode ser requerido por trabalhadores dispensados sem justa causa.
- 05/13/2020
|
Karyopharm Donates 6…,……… Medical Masks Across Massachusetts and the United States in ...
|
SC registra filas de pessoas em busca de seguro-desemprego e auxílio emergencial
- De março a abril, número de pedidos do seguro-desemprego dobrou no estado. Em Joinville, Caixa teve fila na manhã desta terça.
- 05/12/2020
|
Charting a grinding-higher May rally, S&P 500 approaches major resistance
- Technically speaking, the U.S. benchmarks’ grinding-higher recovery attempt remains in play, writes Michael Ashbaugh, though amid increasingly uneven price...
- 05/12/2020
|
Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
- NEWTON, Mass., May 12, 2020 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief.
- 05/12/2020
|
Karyopharm to Participate at —…—… RBC Capital Markets Global Healthcare Virtual Conference
|
Pedidos de seguro-desemprego crescem de 22,1% em abril
- O número de pedidos de seguro-desemprego em abril registrou uma alta de 22,1%, na comparação anual. Clique para saber mais
- 05/11/2020
|
Pedidos de seguro-desemprego crescem 22% no mês passado em relação a abril de 2019, diz governo
- Segundo dados do Ministério da Economia, foram 135.575 pedidos a mais em abril deste ano que em abril de 2019. Em relação a março deste ano, aumento foi de 39,4%.
- 05/11/2020
|
Boy takes on challenge with twin despite battling 3 brain tumours
- Well done boys!
- 05/10/2020
|
How Intel Is Helping Accelerate the Uptake of AI in India
- India has ushered in a data revolution, changing the financial landscape of the country and ensuring the inclusion of a larger part of the population in the digital mainstream. Indian businesses, the government and individuals have, in recent years, seen multiple use cases of artificial intelligence (AI) in various facets of life. Digital assistants, cab…
- 05/08/2020
|
Fairmount Funds Management LLC Buys Zogenix Inc, Amicus Therapeutics Inc, Axsome Therapeutics ...
|
Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade
- Market forces rained on the parade of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shareholders today, when the analysts...
- 05/06/2020
|
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $40
|
Were Hedge Funds Right About Karyopharm Therapeutics Inc (KPTI)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 05/05/2020
|
Karyopharm Therapeutics Inc (KPTI) Q1 2020 Earnings Call Transcript
- KPTI earnings call for the period ending March 31, 2020.
- 05/05/2020
|
SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $29
|
Charting a May whipsaw, S&P 500 holds key support to start worst six months seasonally
- Technically speaking, the S&P 500 has maintained key support (2,793) amid a market whipsaw to start the worst six months seasonally, writes Michael Ashbaugh.
- 05/05/2020
|
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates
- Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -11.43% and -15.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2020
|
Antengene Reports Broadened Partnership, Territory Expansion Deal With Karyopharm For Development, Commercialization Of 4 Oral Novel Drugs, Candidates
|
Recap: Karyopharm Therapeutics Q1 Earnings
- Shares of Karyopharm Therapeutics (NASDAQ:KPTI) fell 9% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 28.44% year over year to ($0.78), which missed the estimate of ($0.69).Revenue of $18,138,000 higher by 11601.94% from the same period last year, which missed the estimate of $21,280,000.Outlook Earnings guidance hasn't been issued by the company for now.Karyopharm Therapeutics hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: May 05, 2020View more earnings on KPTITime: 02:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/ogantstvRecent Stock Performance 52-week high: $29.6152-week low: $4.26Price action over last quarter: Up 23.60%Company Overview Karyopharm Therapeutics Inc is a pharmaceutical company. The company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Its pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor, as well as its lead product, include XPOVIO.See more from Benzinga * PQ Group: Q1 Earnings Insights * Adient: Q2 Earnings Insights * Recap: Asbury Automotive Group Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/05/2020
|
Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended March 31, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor), and provided an overview of its key clinical development programs.
- 05/05/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
- 05/05/2020
|
Why Karyopharm (KPTI) Might Surprise This Earnings Season
- Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/04/2020
|
Veterinary Oncology Market Size 2020 Analysis By Worldwide Industry Trends, Share, Gross Margin, Future Demand, Investment Opportunities, Analysis and Forecast by Top Leading Players till 2026
- May 04, 2020 (The Expresswire) --
Global “Veterinary Oncology Market” is a comprehensive research that provides information regarding Veterinary Oncology...
- 05/04/2020
|
Why Karyopharm (KPTI) Might Surprise This Earnings Season
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
GlycoMimetics (GLYC) Receives a Rating Update from a Top Analyst
- H.C. Wainwright analyst Edward White maintained a Buy rating on GlycoMimetics (GLYC) today and set a price target of $16.00. The company's shares closed
- 05/01/2020
|
GlycoMimetics (GLYC) Receives a Rating Update from a Top Analyst
- H.C. Wainwright analyst
Edward White
maintained a
Buy
rating on GlycoMimetics (
GLYC
–
Research Report
) today and set a price target of
$16.00
. The company’s shares closed last Friday at $2.57, close to its 52-week low of $1.83.
According to
TipRan
- 05/01/2020
|
Veja as oportunidades de emprego no Sine em 7 cidades de SC
- Há vagas em Blumenau, Chapecó, Florianópolis, Itajaí, Joinville, Criciúma e Lages.
- 05/01/2020
|
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Agios Pharma (AGIO) and Eiger Biopharmaceuticals (EIGR)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN), Agios Pharma (AGIO) and
- 05/01/2020
|
H.C. Wainwright Reiterates a Buy Rating on Puma Biotechnology (PBYI)
- H.C. Wainwright analyst Edward White reiterated a Buy rating on Puma Biotechnology (PBYI) today and set a price target of $15.00. The company's shares
- 05/01/2020
|
H.C. Wainwright Reiterates a Buy Rating on Puma Biotechnology (PBYI)
- H.C. Wainwright analyst
Edward White
reiterated a
Buy
rating on Puma Biotechnology (
PBYI
–
Research Report
) today and set a price target of
$15.00
. The company’s shares closed last Thursday at $10.05, close to its 52-week low of $5.50.
According t
- 05/01/2020
|
Acceleron Pharma (XLRN) Receives a Buy from H.C. Wainwright
- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Acceleron Pharma (XLRN), with a price target of $137.00. The
- 05/01/2020
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 56'5(c)(4)
|
PROMETRIKA and Karyopharm: Partners in Global COVID-19 Trial
- Partners in Global COVID-19 Trial
- 04/30/2020
|
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Deciphera Pharmaceuticals (DCPH) and Constellation Pharmaceuticals (CNST)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS), Deciphera Pharmaceuticals (DCPH)
- 04/30/2020
|
Analysts Offer Insights on Healthcare Companies: Universal Health (NYSE: UHS), Deciphera Pharmaceuticals (NASDAQ: DCPH) and Constellation Pharmaceuticals (NASDAQ: CNST)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (
UHS
–
Research Report
), Deciphera Pharmaceuticals (
DCPH
–
Research Report
) and Constellation Pharmaceuticals (
CNST
–
Research Report
- 04/30/2020
|
Analysts Offer Insights on Healthcare Companies: Vaxart (VXRT), Karyopharm Therapeutics (KPTI) and Krystal Biotech (KRYS)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vaxart (VXRT), Karyopharm Therapeutics (KPTI) and Krystal
- 04/30/2020
|
Analysts Offer Insights on Healthcare Companies: Vaxart (NASDAQ: VXRT), Karyopharm Therapeutics (NASDAQ: KPTI) and Krystal Biotech (NASDAQ: KRYS)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vaxart (
VXRT
–
Research Report
), Karyopharm Therapeutics (
KPTI
–
Research Report
) and Krystal Biotech (
KRYS
–
Research Report
) with bullish sentiment
- 04/30/2020
|
Analysts Are Bullish on Top Healthcare Stocks: Aeglea Biotherapeutics (AGLE), uniQure (QURE)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aeglea Biotherapeutics (AGLE) and uniQure (QURE) with
- 04/30/2020
|
Analysts Are Bullish on Top Healthcare Stocks: Aeglea Biotherapeutics (AGLE), uniQure (QURE)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aeglea Biotherapeutics (
AGLE
–
Research Report
) and uniQure (
QURE
–
Research Report
) with bullish sentiments.
Aeglea Biotherapeutics (AGLE)
In a report
- 04/30/2020
|
Emerald Advisers Inc Buys BellRing Brands Inc, Blueprint Medicines Corp, Science Applications ...
|
Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
- - A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study - NEWTON, Mass.,.
- 04/29/2020
|
Should You Buy Stock Now in This New Coronavirus Drug Developer?
- Large and small drug developers and academic researchers are furiously testing and hoping to find one or more treatments for COVID-19. While novel drugs aimed specifically at the coronavirus could potentially yield the greatest effects, the quickest route to a treatment might lie in repurposing existing drugs. Last week, Karyopharm Therapeutics (NASDAQ: KPTI) entered the fray of drug developers seeking to find solutions for those suffering from COVID-19.
- 04/29/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chimerix (CMRX) and Sarepta Therapeutics (SRPT) with
- 04/29/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chimerix (CMRX
- 04/29/2020
|
Karyopharm Announces Data from Phase ' BOSTON Study Selected for Late-Breaking Oral ...
|
Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020
- -- Conference Call Scheduled for Tuesday, May 5, 2020, at 8:30 a.m. ET -- NEWTON, Mass., April 28, 2020 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it.
- 04/28/2020
|
Charting a slow-motion breakout attempt, S&P 500 challenges major resistance (2,874)
- Technically speaking, the S&P 500’s jagged April recovery attempt remains in play amid still receding market volatility, writes Michael Ashbaugh.
- 04/28/2020
|
H.C. Wainwright Thinks Spectrum Pharmaceuticals' Stock is Going to Recover
- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Spectrum Pharmaceuticals (SPPI), with a price target of $11.00.
- 04/28/2020
|
H.C. Wainwright Thinks Spectrum Pharmaceuticals’ Stock is Going to Recover
- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Spectrum Pharmaceuticals (SPPI – Research
- 04/28/2020
|
H.C. Wainwright Believes Syndax Pharmaceuticals (SNDX) Still Has Room to Grow
- H.C. Wainwright analyst Edward White reiterated a Buy rating on Syndax Pharmaceuticals (SNDX) today and set a price target of $19.00. The company's shares
- 04/28/2020
|
H.C. Wainwright Believes Syndax Pharmaceuticals (NASDAQ: SNDX) Still Has Room to Grow
- H.C. Wainwright analyst
Edward White
reiterated a
Buy
rating on Syndax Pharmaceuticals (
SNDX
–
Research Report
) today and set a price target of
$19.00
. The company’s shares closed last Monday at $11.51, close to its 52-week high of $12.28.
Accordi
- 04/28/2020
|
Karyopharm to Report First Quarter —…—… Financial Results on May 5, —…—…
|
Aileron Therapeutics (ALRN) Receives a Buy from H.C. Wainwright
- H.C. Wainwright analyst Edward White reiterated a Buy rating on Aileron Therapeutics (ALRN) on April 22 and set a price target of $3.00. The company's
- 04/27/2020
|
Aileron Therapeutics (ALRN) Receives a Buy from H.C. Wainwright
- H.C. Wainwright analyst
Edward White
reiterated a
Buy
rating on Aileron Therapeutics (
ALRN
–
Research Report
) on April 22 and set a price target of
$3.00
. The company’s shares closed last Friday at $0.53.
According to
TipRanks.com
, White is a top
- 04/27/2020
|
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), AbbVie (ABBV) and Sanofi (OtherSNYNF)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (PTCT), AbbVie (ABBV) and Sanofi
- 04/27/2020
|
H.C. Wainwright Thinks TRACON Pharmaceuticals' Stock is Going to Recover
- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TRACON Pharmaceuticals (TCON), with a price target of $4.00. The
- 04/24/2020
|
H.C. Wainwright Thinks TRACON Pharmaceuticals’ Stock is Going to Recover
- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TRACON Pharmaceuticals (TCON – Research
- 04/24/2020
|
Your 2 Top Profit Opportunities in 2020
- These two underrated biotech stocks have the potential to soar.
- 04/23/2020
|
Drugmakers’ financial fortunes during Covid-19 may hinge on their product mix
- Analyst reports over the past few weeks have looked into what effects the Covid-19 pandemic could have on drugmakers' sales, examining multiple factors. But virtual launches and telemedicine could mitigate some market challenges.
- 04/23/2020
|
Karyopharm (KPTI) Bulls Find More Reasons to Smile
- The race for a COVID-19 treatment is in full throttle, as trials ramp up across the globe almost on a daily basis.On Monday, Karyopharm Therapeutics (KPTI) announced the first subject has been dosed in a Phase 2 study assessing Xpovio (Selinexor) in severely ill COVID-19 patients.The drug is an orally selective inhibitor of nuclear export compound designed to block XPO1, a nuclear export protein. XPO1 has a significant role in the replication of SARS-CoV-2 and in the inflammatory reaction to the virus.The Phase 2 trial is taking place at clinical sites in the U.S. Europe, and Israel, with the goal of enrolling roughly 230 patients. The trial’s primary endpoint is the time to clinical improvement according to the Ordinal Scale.Xpovio has already been making waves with its capacity to treat very severe forms of multiple myeloma (MM), for which it already has FDA approval. Market research company PharmaIntelligence forecasts sales of Xpovio will reach $746 million by 2026.Accordingly, over the trailing twelve months, the share price has appreciated by an enormous 440%. But H.C. Wainwright’s Edward White believes there’s more to come, and not necessarily because of the COVID-19 related opportunity.White said, “While we believe Xpovio could succeed in COVID-19, we do not yet include a launch for this indication in our valuation. We suggest that investors continue to focus on the sNDA submission based on the BOSTON data and the potential approval of Xpovio in DLBCL (diffuse large B-cell lymphoma), both of which are still expected in 2Q20.”To this end, the 5-star analyst keeps his Buy rating on Karyopharm as is, along with a $43 price target. Investors will be seeing gains in the shape of an impressive 73%, should White’s thesis play out in the coming months. (To watch White’s track record, click here)Karyopharm has strong backing from the rest of the Street. Barring a single Hold, all 6 other analysts to have published a review over the last 3 months recommend KPTI stock as a Buy. The strong Buy consensus rating is accompanied with a $33.71 price target and implies upside of nearly 36%. (See Karyopharm stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * Analyst Believes Potential COVID-19 Treatment Can Push Ahersys (ATHX) Stock up to $12 * BioNTech (BNTX) Stock Could Stay Grounded... For Now * Microsoft Reveals 4 New Surface Products Including Release Date For $199 Earbuds * All Eyes on Uber, Lyft Ahead of Earnings; Top Analyst Says 'Buy'
- 04/22/2020
|
Market bears resurface, S&P 500 reverses from major resistance
- Technically speaking, the major U.S. benchmarks are back on the defensive, pressured amid plunging crude-oil prices, writes Michael Ashbaugh.
- 04/21/2020
|
Syndax Pharmaceuticals (SNDX) Gets a Buy Rating from H.C. Wainwright
- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Syndax Pharmaceuticals (SNDX), with a price target of $18.00. The
- 04/21/2020
|
Syndax Pharmaceuticals (SNDX) Gets a Buy Rating from H.C. Wainwright
- In a report released today,
Edward White
from H.C. Wainwright maintained a
Buy
rating on Syndax Pharmaceuticals (
SNDX
–
Research Report
), with a price target of
$18.00
. The company’s shares closed last Tuesday at $10.24.
According to
TipRanks.com
- 04/21/2020
|
Exelixis (EXEL) Receives a Buy from Barclays
- In a report released yesterday, Peter Lawson from Barclays maintained a Buy rating on Exelixis (EXEL), with a price target of $30.00. The company's shares
- 04/21/2020
|
Exelixis (EXEL) Receives a Buy from Barclays
- In a report released yesterday,
Peter Lawson
from Barclays maintained a
Buy
rating on Exelixis (
EXEL
–
Research Report
), with a price target of
$30.00
. The company’s shares closed last Monday at $23.58, close to its 52-week high of $24.90.
Accordi
- 04/21/2020
|
H.C. Wainwright Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)
- H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics (KPTI) today and set a price target of $43.00. The company's
- 04/20/2020
|
H.C. Wainwright Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)
- H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a
- 04/20/2020
|
Karyopharm Announces Dosing Of First Patient In Randomized Study Evaluating Low Dose Selinexor In Patients With Severe Coronavirus (COVID-19)
|
Geode Capital Management LLC Has $15.85 Million Stock Holdings in Karyopharm Therapeutics Inc (NASDAQ:KPTI)
- Geode Capital Management LLC boosted its stake in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 826,972 shares of the company’s stock after purchasing an additional 39,093 shares during the quarter. Geode Capital Management LLC owned […]
- 04/18/2020
|
Analysts Have Conflicting Sentiments on These Healthcare Companies: Danaher (DHR), Theratechnologies (THTX) and Galapagos (GLPG)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR), Theratechnologies (THTX) and Galapagos (GLPG). Danaher
- 04/16/2020
|
H.C. Wainwright Sticks to Their Buy Rating for Clovis Oncology (CLVS)
- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology (CLVS), with a price target of $27.00. The
- 04/15/2020
|
H.C. Wainwright Sticks to Their Buy Rating for Clovis Oncology (CLVS)
- In a report released today,
Edward White
from H.C. Wainwright maintained a
Buy
rating on Clovis Oncology (
CLVS
–
Research Report
), with a price target of
$27.00
. The company’s shares closed last Tuesday at $7.11.
According to
TipRanks.com
, White
- 04/15/2020
|
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Shares Bought by Bank of New York Mellon Corp
- Bank of New York Mellon Corp raised its position in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 21.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 291,093 shares of the company’s stock after acquiring an additional 50,806 shares during the quarter. Bank of New York Mellon Corp’s holdings in Karyopharm Therapeutics were worth $5,580,000 as […]
- 04/15/2020
|
Charting the repair process, S&P 500 approaches next major test
- Technically speaking, the process of repairing extensive damage to the major U.S. benchmarks remains underway, writes Michael Ashbaugh.
- 04/14/2020
|
Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin's Lymphoma
- Antengene announced today that it has dosed the first patient in Taiwan, China in its phase 1 open-label clinical trial of ATG-019 (KPT-9274), a dual inhibitor of both PAK4 and NAMPT. This trial is being conducted to evaluate the safety and tolerability of ATG-019 monotherapy or ATG-019 combined with
- 04/14/2020
|
RBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
- RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI) today and set a price target of $34.00. The company's shares
- 04/13/2020
|
RBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
- RBC Capital analyst
Brian Abrahams
maintained a
Buy
rating on Karyopharm Therapeutics (
KPTI
–
Research Report
) today and set a price target of
$34.00
. The company’s shares closed last Thursday at $20.53.
According to
TipRanks.com
, Abrahams is a 5
- 04/13/2020
|
Constellation Pharmaceuticals (CNST) Gets a Buy Rating from RBC Capital
- RBC Capital analyst Brian Abrahams maintained a Buy rating on Constellation Pharmaceuticals (CNST) today and set a price target of $45.00. The company's
- 04/13/2020
|
Enanta Pharmaceuticals (ENTA) Gets a Hold Rating from RBC Capital
- RBC Capital analyst Brian Abrahams maintained a Hold rating on Enanta Pharmaceuticals (ENTA) today and set a price target of $49.00. The company's shares
- 04/13/2020
|
Enanta Pharmaceuticals (ENTA) Gets a Hold Rating from RBC Capital
- RBC Capital analyst
Brian Abrahams
maintained a
Hold
rating on Enanta Pharmaceuticals (
ENTA
–
Research Report
) today and set a price target of
$49.00
. The company’s shares closed last Thursday at $53.04.
According to
TipRanks.com
, Abrahams is a 5
- 04/13/2020
|
Intercept Pharma (ICPT) Receives a Buy from RBC Capital
- RBC Capital analyst Brian Abrahams maintained a Buy rating on Intercept Pharma (ICPT) today and set a price target of $117.00. The company's shares closed
- 04/13/2020
|
